NCT05862649Completed
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
A Multicenter Longitudinal Study to Evaluate the Correlation Between Oculometric Measures and Clinical Assessment in Patients With Idiopathic Parkinson's Disease (PALOMA Trial)
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. This study aims to evaluate the correlation between oculometric measures and clinical assessment over time, as well as the potential to detect early change in clinical status using an oculometric assessment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 300 (actual)
- First submitted
- 8 May 2023
- Start date
- 21 Aug 2023
- Primary completion date
- 2 Mar 2026
- Lead sponsor
- NeuraLight
- Diseases
- Parkinson disease
- NCT number
- NCT05862649
What you commit to
- Study type: Interventional
- Participants enrolled: 300
- From 21 Aug 2023 to the primary completion date, 2 Mar 2026
- 5 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drug or alcohol abuse (except for using medical cannabis during 24 hours prior NL examination date)
Other illness
- Personal or 1st degree relative history of epilepsy
- Additional neurological diseases
Other
- Inability to sit for 40 minutes on a chair in a calm manner
- Pregnancy or a potential pregnancy (self-declaration)
Who the study is looking for
- Men and women with idiopathic PD (Hoehn \& Yahr scale 1-2)
- Age between 40 and 85 years old
- 0 to 5 years' time since diagnosis
- Normal or corrected vision
- Ability to follow instructions
- Willing and able to sign an informed consent form
- No anticipated changes in PD medications from baseline throughout the study duration based on clinical status during screening
- If treated, stable on treatment for at least 3 months
Age in the registry: 40 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
| Instituto de Biomedicina de Sevilla (IBiS) Coordinator of this site? Confirm its status | Seville | Spain | Unknown status |
| The VCTC Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
| AIBILI research center Coordinator of this site? Confirm its status | Coimbra | Portugal | Unknown status |
| RUSH University Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.